Promising Dup15q drug trial halted early
NCT ID NCT05307679
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called basmisanil in children aged 2 to 14 with Dup15q syndrome, a rare genetic condition that affects development. The goal was to see if the drug could improve daily living skills like communication and movement. The trial was stopped early after enrolling only 7 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUP15Q SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90010, United States
-
Evelina London Children's Hospital
London, SE1 7EH, United Kingdom
-
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, 08950, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Rush University Medical Center
Chicago, Illinois, 60612-3244, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.